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Abstract
Background: In Australia two acellular Bordetella pertussis vaccines have replaced the use of a
whole cell vaccine. Both of the licensed acellular vaccines contain the following three components;
pertussis toxoid, pertussis filamentous haemagglutinin and the 69 kDa pertactin adhesin. One
vaccine also contains pertussis fimbriae 2 and 3. Various researchers have postulated that herd
immunity due to high levels of pertussis vaccination might be influencing the makeup of endemic B.
pertussis  populations by selective pressure for strains possessing variants of these genes, in
particular the pertactin gene type. Some publications have suggested that B. pertussis variants may
be contributing to a reduced efficacy of the existing vaccines and a concomitant re-emergence of
pertussis within vaccinated populations. This study was conducted to survey the pertactin and
pertussis toxin subunit 1 types from B. pertussis isolates in Queensland, Australia following the
introduction of acellular vaccines.
Methods: Forty-six B. pertussis isolates recovered from Queensland patients between 1999 and
2003 were examined by both DNA sequencing and LightCycler™ real time PCR to determine their
pertactin and pertussis toxin subunit 1 genotypes.
Results: Pertactin typing showed that 38 isolates possessed the prn1 allele, 3 possessed the prn2
allele and 5 possessed the prn3 allele. All forty-six isolates possessed the pertussis toxin ptxS1A
genotype. Amongst the circulating B. pertussis population in Queensland, 82.5% of the recovered
clinical isolates therefore possessed the prn1/ptxS1A genotype.
Conclusion: The results of this study compared to historical research on Queensland isolates
suggest that B. pertussis pertactin and pertussis toxin variants are not becoming more prevalent in
Queensland since the introduction of the acellular vaccines. Current prevalences of pertactin
variants are significantly different to that described in a number of other countries with high vaccine
coverage. Relative paucity of recovered isolates compared to notified infections, due primarily to
non culture based pertussis diagnostics is however a confounding factor in the assessment of
variant prevalence.
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Background
Bordetella pertussis, the etiological agent of 'Whooping
Cough' remains prevalent in Australia despite the intro-
duction and wide spread use of pertussis vaccines as part
of the childhood immunisation scheme. The Australian
standard vaccination schedule for pertussis consists of
acellular vaccines given in doses at 2, 4 and 6 months, fol-
lowed by a fourth dose at 4 years and a booster at 15–17
years of age [1]. Prior to 1999 a local whole cell vaccine
was in use beginning in the decade 1936–1945. [2]. An
'Immunise Australia' program established in 1997 has set
a target of 90% coverage for pertussis vaccination [2]. In
the Australian state of Queensland pertussis vaccine cov-
erage in the 1990s moved from the high 70% to mid 80%,
and then rose above the 90% target from 2001 onwards
[2-4]. In spite of this high vaccine coverage, in recent times
pertussis infection has been the most common vaccine
preventable illness in Australia, with epidemics occurring
each 3 to 5 years associated with a background of endemic
circulation [5]. Pertussis notifications per 100,000 of the
Australian population have risen from 4.9 in 1992 to an
average of 34.3 (range: 25.6 to 84.5) through to 2004 [6].
In Queensland, pertussis notifications throughout the
1990s and into the new decade align closely with the
surge evident in the national figures [6]. Many other coun-
tries with high vaccination coverage similar to that in Aus-
tralia have also seen a resurgence of pertussis disease [7-
10]. A number of factors have been postulated for explain-
ing this global resurgence of pertussis disease within
highly vaccinated communities.
Presently the primary cause is thought to be increased
cases in adults and adolescents due to waning immunity,
resulting in a reservoir of infection for non or incom-
pletely vaccinated young children [8,11,12]. Australian
pertussis infection data appears to support this observa-
tion, whereby from 1991 to 2002 approximately 60% of
Australian pertussis notifications occurred in people over
10 years of age [2-4,13]. To address this situation the 'Glo-
bal Pertussis Initiative' has recommended booster immu-
nisation for older children and adolescents [14,15]. This
recommendation has been taken up in Australia from
2004 with the licensing, funding and inclusion of the
GlaxoSmithKline acellular booster 'Boostrix' in the stand-
ard vaccination schedule for 15–17 year olds [1,16].
Underpinning the increase in adult/adolescent notifica-
tions has also been significant improvement in the recog-
nition of pertussis infections in this group through
improved surveillance and the introduction of new testing
methods such as nucleic acid amplification (NAA) and
improved serological diagnosis. Improved immunoassays
targeting both the B. pertussis antigen (IgA) and specifi-
cally in Queensland an anti-pertussis toxin IgG have both
contributed to increased detection and notifications
[13,17,18].
A second hypothesis for explaining the re-emergence of
pertussis disease within highly vaccinated communities is
vaccination-induced B. pertussis evolution, originally ten-
dered in the literature by Mooi et.al [19]. This hypothesis
involves a process whereby herd immunity drives the
emergence of strains possessing variant genes and a result-
ant expression of proteins which are a mismatch with
existing vaccine components. A particular concern based
on this hypothesis is the impact on vaccine efficacies in
light of the trend towards replacement of whole cell vac-
cines (WCV) with acellular vaccines (ACV) containing
only a few select immunogenic antigens. As ACVs contain
only selected B. pertussis antigens such as pertussis toxoid
(PT), pertussis filamentous haemaglutinin (FHA) and
pertactin (PRN), it has been postulated that high levels of
vaccination coverage places selective pressure on the genes
of these vaccine targets. In the first publication suggesting
possible vaccination driven immune evasion adaptations
were occurring in B. pertussis, Mooi and co-workers
described a situation in the Netherlands where prior to
the introduction of a WCV the endemic PRN type was
solely prn1. Post WCV introduction the prn1 frequency
dropped to approximately 10% and the remaining major-
ity were found to belong to the non-vaccine types prn2
and prn3 [9,19]. Since then further evidence supporting
this hypothesis has been noted with significant replace-
ment of vaccine type PRN and PT alleles in the endemic B.
pertussis populations in a number of other European and
American countries, in particular replacement of vaccine
type prn1 and ptxS1B with variants [11].
Whilst a shift in the PRN and PT types has certainly
occurred in a large number of countries, recent work has
suggested that this shift may be independent of the use of
vaccines. Firstly, like continental Europe ptxS1A has also
become predominant in the UK despite the fact that a
highly effective UK WCV actually contains a ptxS1A
derived protein [20]. Also, recent work utilising a mouse
model has shown that ACVs do in fact remain efficacious
against a group of strains which possess variant alleles,
provided that the ACV is of sufficient potency [21]. Fur-
ther more, Japan which has the worlds longest standing
ACV based pertussis vaccination program has not shown
significant emergence, let alone dominance of pertussis
strains possessing PRN or PT differing to the ACVs in use
[22,23]. Recent population profiling of B. pertussis in five
European countries has also shown no correlation
between strain characteristics and the use of differing vac-
cination programs [24]. And a majority of isolates from
those same five European countries also share the same
PFGE profile despite differences in vaccination policies
and vaccine types and contents [25]. Evasion of Bordetella
bacteriophage infection has recently been mooted as a
possible alternate explanation for the observed PRN vari-
ability [11]. A recent review of isolate polymorphism andBMC Infectious Diseases 2006, 6:53 http://www.biomedcentral.com/1471-2334/6/53
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vaccination programs in relation to pertussis re-emer-
gence concluded that to date no direct link has been noted
for PRN and PT variation [11]. The authors do state how-
ever that it is 'possible but not yet proven' that the emer-
gence of variants coupled to waning immunity may have
resulted in the resurgence of pertussis in the older children
and adolescents group, but reiterate that reduced circula-
tion and waning immunity may also have produced a
similar outcome [11].
PRN is a 69-kDa outer membrane protein that mediates
adherence of the bacterium to host cell walls. The majority
of the polymorphism in PRN occurs within a repetitive
element of the gene which contains a variable number of
Gly-Gly-X-X-Pro (GGXXP) repeats [19]. Currently eleven
different PRN allelic types have been discovered through
the use of DNA sequencing [26]. Various methods for the
identification of PRN alleles have been used including full
or partial gene sequencing, shared primer PCR product
size polymorphism, amplification-refractory mutation
system PCR and real time PCR with probes or DNA bind-
ing dyes including product melting curve analysis and
electrophoretic sizing [19,20,26,27]. Full gene DNA
sequencing produces the highest fidelity information on
emerging PRN variants, and uniquely so for those with
mutations outside of the GGXXP region. However, the
size of the PRN gene renders full gene sequencing a time
consuming and moderately costly exercise for allelic typ-
ing. Mäkinen et al. describe two real time PCR assays, that
when used within a scheme specifically identify the
majority of PRN alleles [28]. We have utilised a corrected
adaptation of the Mäkinen et al. scheme (represented in
Figure 1), whereby electrophoretic sizing of all HybProbe
PCR reaction products irrespective of the product melting
point values updates the scheme enabling specific dis-
crimination of the new alleles detected since publication
of the article.
The PT protein is a typical AB exotoxin consisting of five
subunits of which the 269 amino acid S1 subunit encodes
the active toxic function [29,30]. Four polymorphisms
have currently been described for the PT S1 subunit. Com-
monly strains used in vaccines have either the ptxS1B or
ptxS1D  alleles. The detection of PT alleles has until
recently also been performed exclusively by DNA
sequencing, however a paper has been recently published
utilising real-time PCR and product melting curve analysis
for the differentiation of the currently known PT alleles
[31].
In Australia, two acellular B. pertussis vaccines which were
licensed and made available from 1997 have totally
replaced the use of a locally manufactured whole cell vac-
cine since 1999. Both of the licensed ACVs contain the fol-
lowing three components; PT, FHA and PRN. One of the
vaccines also contains pertussis fimbriae 2 and 3. The Aus-
tralian WCV in use until 1999 was manufactured from a
strain possessing prn1 and ptxS1A [32]. The GlaxoSmithK-
line (GSK) acellular vaccine is derived from a strain pos-
sessing  prn1/ptxS1B, the manufacturer of the other
licensed acellular vaccine declined to provide details of
the specific alleles contained in their preparation. This
aim of this study was to investigate circulating PRN and
PT alleles in Queensland B. pertussis isolates post intro-
duction of ACVs. In total, forty-six clinical isolates col-
lected from 1999 to 2003 were available. Publication of
data from 1989–1999 including an earlier collection of
Queensland isolates by Poynten et al. [32] whilst this
work was in progress has also enabled comparisons to be
drawn between the prevalences of alleles between the two
time periods of 1989–1999 and 1999–2003.
Flowchart Depicting Modified Protocols for LightCycler  Based prn Allelic Typing Figure 1
Flowchart Depicting Modified Protocols for LightCy-
cler Based prn Allelic Typing. Modified flowchart of pro-
tocols from Mäkinen et al. detailing the updated procedure 
for LightCycler based allelic typing of the B. pertussis prn gene. 
Electrophoretic sizing of all QH8F-QH2R PCR products 
from the FRET HybProbe assay in addition to melting curve 
analysis enables determination of new alleles detected since 
publication of the original method.BMC Infectious Diseases 2006, 6:53 http://www.biomedcentral.com/1471-2334/6/53
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Methods
Bacterial strains and culture conditions
A total of forty-six unique clinical isolates of B. pertussis
collected and stored from 1999 through 2003 were
retrieved from the frozen culture collections of Public
Health Microbiology, Queensland Health Scientific Serv-
ices and the Microbiology Department of Sullivan Nico-
laides Pathology, Taringa, Brisbane. Frozen isolates were
recovered and grown on Charcoal Agar (Biomerieux Aus-
tralia) incubated at 35°C for four days in moist condi-
tions. Demographic data including patient name, date of
birth, postal code and date of isolation was available for
all strains, but there was very limited information on
patient vaccination history (3 of 46 patients).
Extraction of DNA
Genomic DNA from the B. pertussis isolates was extracted
using the High Pure PCR Template Preparation Kit (Roche
Diagnostics) according to the manufacturers instructions.
PRN and PT typing
Examination of the PRN and PT alleles carried by the iso-
lates was done by DNA sequencing utilising a combina-
tion of the methods of Mooi et al. [19,33], and the
expansion of those methods by Fry et al. [20]. Two over-
lapping amplicons of the pertactin gene were generated
from each DNA extract utilising the primer pairs PR8F/
PRN1618 and BF/PR5R [20]. PCR reactions were per-
formed in 50 µL final volumes comprising 1× GeneAmp
PCR Buffer II (Applied Biosystems), 1.5 mM MgCl2
(Applied Biosystems), 200 µM deoxynucleotides (Amer-
sham Biosciences), 10 pmol of each primer (Geneworks,
Adelaide, Australia), 1.5 Units of AmpliTaq Gold DNA
Polymerase (Applied Biosystems), 10% DMSO (D2438,
Sigma Chemical Co., St Louis) and the remainder up to 48
µL as Water for Injections BP (AstraZeneca). 2 µL of tem-
plate DNA was added to complete the reaction mix. Ther-
mal cycling was performed using a GeneAmp PCR System
9700 thermal cycler (Applied Biosystems) with the fol-
lowing conditions: initial denaturation 95°C for 9 min-
utes, thirty-five cycles consisting of 95°C for 30 seconds,
57°C for 30 seconds and 72°C for 1 minute, a single final
extension of 72°C for 7 minutes and a hold at 4°C.
Sequencing of each of the two overlapping sub-fragments
of the prn gene amplified from each isolate was performed
with the primers used to generate the PCR product as well
as those remaining primers used by Fry et al. [20] which
were located internal to the respective fragment. Cycle
sequencing was performed using the Big Dye Terminator
Cycle Sequencing Ready Reaction Kit V1.1 (Applied Bio-
systems) according to manufacturers instructions. Cycle
sequencing reaction products were purified using sodium
acetate/ethanol precipitation, and subsequently analysed
on an ABI PRISM 377 DNA Sequencer (Applied Biosys-
tems). Sequences were assembled and analysed using
Sequencher 3.0 software (Gene Codes Corporation). The
primer pair S1F/S1R of Mooi et al. [19] were utilised to
amplify the polymorphic region of the PT subunit 1 gene.
The reaction was performed using identical master-mix
and cycling conditions as detailed for the PRN typing
PCR, substituting the S1F/S1R primers. The PT subunit 1
PCR fragments were sequenced also as above using the
three primers S1F, S1R and S1FM [19].
In addition to sequencing, a corrected and modified PRN
typing scheme originally developed by Mäkinen et al. [28]
utilising real time PCR was also applied to investigate the
applicability of this rapid method for Australian isolates.
Allele specific amplification (ASA) was first performed
and samples that were positive were then analysed using
a Förster Resonance Energy Transfer (FRET) hybridisation
probe assay. Both procedures were performed as described
by Mäkinen et al. [28], except that total cycles were
increased to 40 and LightCycler FastStart DNA Master kits
(Roche Diagnostics) were utilised requiring a 10 minute
pre-incubation at 95°C to accommodate the activation of
the FastStart enzyme. Melting curve analysis of products
was performed, followed by post amplification recovery
of all PCR products from the capillaries by inversion cen-
trifugation. Agarose gel electrophoresis using 3% agarose
and a 25 bp DNA ladder (Invitrogen) was then performed
for the determination of PCR product size. Electro-
phoretic sizing of all PCR products is a required modifica-
tion of the original methods in order to successfully use
the Mäkinen et al. [28] scheme with currently known PRN
alleles. In addition we found that the PCR product sizes
for all PRN types described in the text of Mäkinen et al.
[28] are in fact 10 base pairs understated. This observation
was confirmed by software PCR product size prediction
based on the binding sites of primers QH8F and QH2R
within the PRN variant gene sequences stored in Gen-
bank, and by experimental observations of PRN types in
this study (Figure 2). In light of the discovery of new PRN
variants 9 and 11, it now becomes paramount to electro-
phoretically size every positive QH8F/QH2R HybProbe
assay PCR product, preferably with a 25 bp graduated
DNA marker. Since prn11  is identical under the Hyb-
Probes QJ1/QJ2 to prn1, it is predicted to have the same
melting temperature (Tm) value, however the size of the
PCR products differ with prn1 being 270 bp, and prn11
285 bp. Also, as prn9 is identical under the HybProbes to
prn2-4, it would likewise be predicted to have an identical
Tm value to those alleles, however the PCR product size of
300 bp clearly differentiates prn9 from prn2-4.
Statistical analysis
A two tailed Fishers exact test was utilised to test for statis-
tically significant differences between the observed and
historical proportions of the PRN alleles. The two-tailed P
value was calculated by the recommended method ofBMC Infectious Diseases 2006, 6:53 http://www.biomedcentral.com/1471-2334/6/53
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summing small P values. Statistical analysis was per-
formed utilising the online calculators of GraphPad Soft-
ware. At P values <0.05 the distributions of the alleles
cannot be said to be significantly different due to chance
[34]. Sample size calculations were performed using the
online calculators of Raosoft, Inc.
Results and discussion
Age and sex distribution
A slightly higher rate of infection of females over males of
1.3:1 (Table 1) was evident amongst the patients from
which the isolates were collected and is comparable to
that previously described in reviews of Australian pertus-
sis notification data [2-4]. The age distribution of patients
from this collection was <1 years (n = 22), 1–4 years (n =
8), 5–9 years (n = 1), 10–14 years (n = 3) and >15 years
(n = 12). This age distribution agrees with previous
reports which indicate infants who may be only partly or
not-vaccinated have the greatest disease burden [35]. It
also reflects the observation of a re-emergence of pertussis
in the adolescent and adult demographic which has been
reported as the major reservoir for transmission to infants
[15].
Pertactin gene variation
Limited variation was observed in the PRN genes of the 46
Queensland isolates with only three different PRN types
detected. Results are presented in Table 1. The prn1 allele
was identified in 38 of the 46 isolates, prn2 in three of the
46 isolates and prn3 in five of the 46 isolates. The modi-
fied/corrected rapid real-time PCR typing method of Mäk-
inen et al. [28] correctly identified all 46 of the isolates
when compared to full gene sequencing.
From this recent sample it appears that for Queensland B.
pertussis isolates a PRN type similar to that present in an
existing vaccine (prn1) has again returned to prevalence
(82.5%). Prior to 1989, Poynten et al. reported an Aus-
tralia wide prevalence of 81% for prn1 at a time when a
prn1 containing Australian WCV had been in use for fifty
years [32]. Over the next decade (1989–1998) Poynten et
al. subsequently described the emergence of prn2  and
prn3, such that prn1 prevalence had dropped to 47% [32].
Based on the results of this study, over the next five years
proportions of the variants prn2 and particularly prn3 in
Queensland now appear to have dropped remarkably.
Poynten et al. reported the prevalence of prn3 in the 22
Queensland isolates from 1989–1998 as 45% (10 of 22),
associated with a statistically significant increase Australia
wide in the proportion of B. pertussis carrying the variant
prn3 allele between the two time periods, 1967–1985 and
1989–1998 [32]. This collection of 46 isolates from
1999–2003 show that there has now been a statistically
significant decrease (P = 0.0034, two sided Fishers exact
test) in prevalence of prn3 in Queensland compared to
1989–1998, with prn3 now accounting for only 11% (5 of
46) of the Queensland total (Table 2).
This current observation of a fall in prevalence of PRN var-
iants compared to the PRN type contained in a local vac-
cine is in marked contrast to that observed in Europe and
America where PRN variants have emerged, persisted and
significantly replaced isolates possessing a vaccine match-
ing PRN allele [11]. Population studies remain to be done
on these isolates to determine if the observation of a re-
established dominance of prn1 containing vaccine match-
ing strains in Queensland may be a geographic specificity
related to a clonal expansion of a distinct B. pertussis pop-
ulation. Geographic specificity has been noted in associa-
tion with populations of B. pertussis in both Finland and
France [11,24,25,36], and in the persistence of vaccine
QH8F-QH2R PCR Product Sizing Figure 2
QH8F-QH2R PCR Product Sizing. Ethidium bromide 
stained 3% agarose gel electrophoresis of QH8F-QH2R 
primer pair PCR products for sequence confirmed prn1, prn2 
and prn3 containing B. pertussis isolates. Sizing against Invitro-
gen 25 bp DNA Ladder illustrates PCR product sizes of 270 
bp, 285 bp and 270 bp respectively.BMC Infectious Diseases 2006, 6:53 http://www.biomedcentral.com/1471-2334/6/53
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matching strains in Japan [22,23]. Nonetheless, the obser-
vation of a temporal fall in the prevalence of PRN variants
and a re-emergence of a PRN allele which is a match to
existing vaccines is not consistent with significant vaccina-
tion driven change of PRN alleles in the Queensland B.
pertussis population.
PT subunit a gene variation
All 46 isolates in this study possessed the A genotype of
ptxS1. The finding of ptxS1A in all of the recent Queens-
land isolates again shows the predominance of this PT
allele in Australian isolates. Despite the historic Australian
WCV containing ptxS1A, no variation from that pheno-
type was found by Poynten et al. in 62 isolates tested from
the 84 collected between 1967 to 1998 [32]. Although
Poynten et al. did report two new variants (ptxS1F,
ptxS1G) derived from ptxS1A which contain silent muta-
tions and produced the A type protein [32]. The historical
homogeneity of Australian PT alleles is again in marked
contrast to northern hemisphere studies that show a
change of the dominant PT alleles from ptxS1B  and
ptxS1D to ptxS1A following the introduction of vaccines
with non ptxS1A components [9,11,36-39]. Applying the
vaccination driven hypothesis it would appear unlikely
that ptxS1 variants different to ptxS1A will emerge, given
the Australian WCV (ptxS1A) has been replaced by the use
of ACVs containing non ptxS1A components. Of interest
is that no Australian isolate prior to 1967 has been exam-
ined and a ptxS1A containing WCV was in use from the
1936–45 decade. It may be possible that there was a pre-
1967 hereto unrecognised shift in the Australian PT allele
prevalence similar to that of the UK. In the UK, the ptxS1A
allele (as also contained in the UK WCV) began to pre-
dominate over ptxS1B in clinical isolates from the 1950s
and showed 100% prevalence throughout the 1990s [20].
Sampling
A lack of available cultures of B. pertussis from which to
perform PRN and PT profiling over the time period com-
pared to total notifications of pertussis disease is a limita-
tion of this study. It is not possible to state that the
observed fluctuations in variant prevalence from both
studies of Australian isolates to date are free of sampling
artefact. A total of 84 isolates (including 22 from Queens-
land) were collected by Poynten et al. from 1967 through
1998, a period of time where recorded notifications of
pertussis for the years 1991 to 1998 alone were 36172
cases [6]. Combining that data and our own, a very small
sample of only 130 Australian isolates (68 from Queens-
land) have been tested from greater than 41407 notifica-
tions of pertussis through to 2003. Further, the methods
of sampling employed in both studies have been by neces-
sity non-probabilistic, being limited to those cases where
an isolate was recovered from a patient and stored. Non-
probabilistic sampling by definition does not involve ran-
dom selection which otherwise allows calculation of
probability that the sample is indeed representative of the
population it has been drawn from. At best, such conven-
ience sampling may yield good estimates, but no objective
evaluation of the precision of sample results can be
applied. A co-ordinated attempt in Australia to prospec-
tively obtain clinical isolates from new cases of pertussis is
warranted in order to statistically verify these observa-
tions. The problem of obtaining cultured isolates in a
diagnostic environ rightly shifting to rapid methods such
as serology and NAA appears common, and at least one
other author has recently recommended active collection
of B. pertussis strains [24].
Conclusion
The results of this study compared to historical research
on Queensland isolates indicate that B. pertussis possess-
Table 1: Queensland Bordetella pertussis Sample Petactin and Pertussis Toxin Alleles 1999–2003
Year Number of PRN Types PT (All ptxS1A) Ages or (Median) Female:Male
prn1 prn2 prn3
1 9 9 9 3003 1 , 6 3 , 4 6 1 : 2
2 0 0 0 1012 1 , 1 2 : 0
2001 9 0 1 10 (5) 8:2
2002 21 2 3 26 (<6 m) 12:14
2 0 0 3 4105 3  m , 1 1  m , 3 , 2 , 2 3 : 2
Table 2: Frequency of Queensland Bordetella pertussis Sample Pertactin Alleles 1999–2003
prn Type Number Percentage of Total
13 8 8 2 . 5 %
236 . 5 %
351 1 %BMC Infectious Diseases 2006, 6:53 http://www.biomedcentral.com/1471-2334/6/53
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ing variant PRN alleles to those in the existing vaccines
were less prevalent in Queensland in the five years since
the introduction of the Australian ACVs. Whilst the num-
bers of isolates tested in Australian studies to date consign
the data to being a good estimate (at best) rather than
being considered statistically valid, an observed return to
prevalence of a PRN type identical to that in historical and
current local vaccines differs markedly from that seen in
many other countries following the introduction of vac-
cine programs. At present no divergence from the PT
ptxS1A encoded phenotype has been detected in the lim-
ited number of B. pertussis strains examined in Australia
from 1967 to 2003 despite the historic Australian pertus-
sis WCV containing ptxS1A derived proteins. The study
data appears to support the view that changes in epidemi-
ology and transmission of pertussis coupled to a shift of
the disease from young children to adults/adolescents
(and then by association to naive infants) due to waning
immunity is the most likely explanation for pertussis re-
emergence. Nonetheless, as others have suggested it will
continue to remain important to prospectively profile
endemic B. pertussis for variant genes of the proteins con-
tained in the ACVs [22]. The relative paucity of recovered
isolates compared to notified infections, due primarily to
non culture based pertussis diagnostics is a confounding
factor in the assessment of variant allele prevalence. In the
interests of effective long term monitoring of ACV effi-
cacy, for all instances of suspected pertussis infection
medical practitioners should also consider submitting
samples suitable for culture in addition to requesting
rapid diagnostics. Our modifications of the rapid real
time PCR method of Mäkinen et al. [28] are currently an
acceptable protocol for rapid screening of PRN variants in
Australian isolates. We propose to attempt allele typing
on DNA extracts from clinical samples which are positive
for B. pertussis DNA utilising this modified rapid method
in order to improve future monitoring in Queensland in
the absence of available cultures.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SB initiated the study collaborative; ATS and SB per-
formed the laboratory work and contributed equally to
the final version of the manuscript.
Acknowledgements
The authors would like to acknowledge the contributions of the following 
people for their valuable assistance in isolate retrieval and cultivation; Ms 
Vicki Hicks, Mr John Bates, Dr Jenny Robson, Mr Rodney McDougall and 
Ms Jacqui Schooneveldt. We would additionally like to thank Professor Frits 
Mooi for supplying prn10 sequence information prior to its submission into 
Genbank, and statistician Dr Helen Johnson for performing and reviewing 
the statistical components.
References
1. The Australian Immunisation Handbook.  8th edition. Can-
berra, National Health and Medical Research Council.; 2003. 
2. McIntyre P, Amin J, Gidding H, Hull B, Torvaldsen S, Tucker A, Turn-
bull F, Burgess M: Vaccine preventable diseases and vaccina-
tion coverage in Australia, 1993-1998.  Commun Dis Intell 2000,
Suppl:v-83.
3. Vaccine-preventable diseases and vaccination coverage in
Australia, 1999-2000.  N S W Public Health Bull 2003, 14:94.
4. Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B, Law-
rence G, MacIntyre R, Wood N, Armstrong D: Vaccine preventa-
ble diseases and vaccination coverage in Australia 2001 to
2002.  Commun Dis Intell 2004, 28 Suppl 2:vii-S116.
5. Miller M, Roche P, Yohannes K, Spencer J, Bartlett M, Brotherton J,
Hutchinson J, Kirk M, McDonald A, Vadjic C: Australia's notifiable
diseases status, 2003: Annual report of the National Notifia-
ble Diseases Surveillance System.  Commun Dis Intell 2005,
29:1-61.
6. National Notifiable Diseases Surveillance System   [http://
www1.health.gov.au/cda/Source/Rpt_4_sel.cfm]
7. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke
HC, Conyn-van Spaendonck MA: Reemergence of pertussis in
the highly vaccinated population of the Netherlands: obser-
vations on surveillance data.  Emerg Infect Dis 2000, 6:348-357.
8. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E,
Wharton M, Livengood JR: Changing epidemiology of pertussis
in the United States: increasing reported incidence among
adolescents and adults, 1990-1996.  Clin Infect Dis 1999,
28:1230-1237.
9. Mooi FR, van Loo IH, King AJ: Adaptation of Bordetella pertussis
to vaccination: a cause for its reemergence?  Emerg Infect Dis
2001, 7:526-528.
10. Bass JW, Wittler RR: Return of epidemic pertussis in the
United States.  Pediatr Infect Dis J 1994, 13:343-345.
11. Godfroid F, Denoel P, Poolman J: Are vaccination programs and
isolate polymorphism linked to pertussis re-emergence?
Expert Rev Vaccines 2005, 4:757-778.
12. von Konig CH, Halperin S, Riffelmann M, Guiso N: Pertussis of
adults and infants.  Lancet Infect Dis 2002, 2:744-750.
13. Andrews R, Herceg A, Roberts C: Pertussis notifications in Aus-
tralia, 1991 to 1997.  Commun Dis Intell 1997, 21:145-148.
14. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D,
Guiso N, Heininger U, Schellekens J, Tan T, von Konig CH, Plotkin S:
New pertussis vaccination strategies beyond infancy: recom-
mendations by the global pertussis initiative.  Clin Infect Dis
2004, 39:1802-1809.
15. Forsyth K, Tan T, von Konig CH, Caro JJ, Plotkin S: Potential strat-
egies to reduce the burden of pertussis.  Pediatr Infect Dis J 2005,
24:S69-74.
16. Forsyth K, Nagai M, Lepetic A, Trindade E: Pertussis immuniza-
tion in the global pertussis initiative international region:
recommended strategies and implementation considera-
tions.  Pediatr Infect Dis J 2005, 24:S93-7.
17. Poynten M, Hanlon M, Irwig L, Gilbert GL: Serological diagnosis of
pertussis: evaluation of IgA against whole cell and specific
Bordetella pertussis antigens as markers of recent infection.
Epidemiol Infect 2002, 128:161-167.
18. Notifiable Diseases Report 1997-2001   [http://
www.health.qld.gov.au/phs/Documents/cdu/15896.pdf]
19. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra
W, Willems RJ: Polymorphism in the Bordetella pertussis vir-
ulence factors P.69/pertactin and pertussis toxin in The
Netherlands: temporal trends and evidence for vaccine-
driven evolution.  Infect Immun 1998, 66:670-675.
20. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC:
Genotypic variation in the Bordetella pertussis virulence fac-
tors pertactin and pertussis toxin in historical and recent
clinical isolates in the United Kingdom.  Infect Immun 2001,
69:5520-5528.
21. Denoel P, Godfroid F, Guiso N, Hallander H, Poolman J: Compari-
son of acellular pertussis vaccines-induced immunity against
infection due to Bordetella pertussis variant isolates in a
mouse model.  Vaccine 2005, 23:5333-5341.
22. Guiso N, Boursaux-Eude C, Weber C, Hausman SZ, Sato H, Iwaki M,
Kamachi K, Konda T, Burns DL: Analysis of Bordetella pertussisPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Infectious Diseases 2006, 6:53 http://www.biomedcentral.com/1471-2334/6/53
Page 8 of 8
(page number not for citation purposes)
isolates collected in Japan before and after introduction of
acellular pertussis vaccines.  Vaccine 2001, 19:3248-3252.
23. Kodama A, Kamachi K, Horiuchi Y, Konda T, Arakawa Y: Antigenic
divergence suggested by correlation between antigenic vari-
ation and pulsed-field gel electrophoresis profiles of Borde-
tella pertussis isolates in Japan.  J Clin Microbiol 2004,
42:5453-5457.
24. van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hal-
lander HO, Bondeson K, von Konig CH, Riffelmann M, Vahrenholz C,
Guiso N, Caro V, Njamkepo E, He Q, Mertsola J, Mooi FR: Analysis
of Bordetella pertussis populations in European countries
with different vaccination policies.  J Clin Microbiol 2005,
43:2837-2843.
25. Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hal-
lander HO, He Q, Mertsola J, Riffelmann M, Vahrenholz C, Von Konig
CH, Guiso N: Pulsed-field gel electrophoresis analysis of Bor-
detella pertussis populations in various European countries
with different vaccine policies.  Microbes Infect 2005, 7:976-982.
26. Muyldermans G, Pierard D, Hoebrekx N, Advani R, Van Amersfoorth
S, De Schutter I, Soetens O, Eeckhout L, Malfroot A, Lauwers S: Sim-
ple Algorithm for Identification of Bordetella pertussis Pert-
actin Gene Variants.  J Clin Microbiol 2004, 42:1614-1619.
27. Fiett J, Letowska I, Gniadkowski M, Hryniewicz W: The new strat-
egy for allele identification of the genes coding for pertussis
toxin subunit S1 (ptx S1) and pertactin (prn) in Bordetella
pertussis.  J Microbiol Methods 2003, 55:651-666.
28. Makinen J, Viljanen MK, Mertsola J, Arvilommi H, He Q: Rapid iden-
tification of Bordetella pertussis pertactin gene variants
using LightCycler real-time polymerase chain reaction com-
bined with melting curve analysis and gel electrophoresis.
Emerg Infect Dis 2001, 7:952-958.
29. Tamura M, Nogimori K, Murai S, Yajima M, Ito K, Katada T, Ui M, Ishii
S:  Subunit structure of islet-activating protein, pertussis
toxin, in conformity with the A-B model.  Biochemistry 1982,
21:5516-5522.
30. Sekura RD, Fish F, Manclark CR, Meade B, Zhang YL: Pertussis
toxin. Affinity purification of a new ADP-ribosyltransferase.
J Biol Chem 1983, 258:14647-14651.
31. Makinen J, Mertsola J, Viljanen MK, Arvilommi H, He Q: Rapid typ-
ing of Bordetella pertussis pertussis toxin gene variants by
LightCycler real-time PCR and fluorescence resonance
energy transfer hybridization probe melting curve analysis.  J
Clin Microbiol 2002, 40:2213-2216.
32. Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL: Tem-
poral trends in circulating Bordetella pertussis strains in
Australia.  Epidemiol Infect 2004, 132:185-193.
33. Mooi FR, Hallander H, Wirsing von Konig CH, Hoet B, Guiso N: Epi-
demiological typing of Bordetella pertussis isolates: recom-
mendations for a standard methodology.  Eur J Clin Microbiol
Infect Dis 2000, 19:174-181.
34. Strike PW: Statistical Methods in Laboratory Medicine.
Oxford, Butterworth Heinemann; 1991. 
35. Greenberg DP, von Konig CH, Heininger U: Health burden of per-
tussis in infants and children.  Pediatr Infect Dis J 2005, 24:S39-43.
36. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N: Polymor-
phism of Bordetella pertussis isolates circulating for the last
10 years in France, where a single effective whole-cell vac-
cine has been used for more than 30 years.  J Clin Microbiol 2001,
39:4396-4403.
37. Mooi FR, He Q, van Oirschot H, Mertsola J: Variation in the Bor-
detella pertussis virulence factors pertussis toxin and pertac-
tin in vaccine strains and clinical isolates in Finland.  Infect
Immun 1999, 67:3133-3134.
38. Kourova N, Caro V, Weber C, Thiberge S, Chuprinina R, Tseneva G,
Guiso N: Comparison of the Bordetella pertussis and Borde-
tella parapertussis isolates circulating in Saint Petersburg
between 1998 and 2000 with Russian vaccine strains.  J Clin
Microbiol 2003, 41:3706-3711.
39. Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T:
Polymorphism in Bordetella pertussis pertactin and pertus-
sis toxin virulence factors in the United States, 1935-1999.  J
Infect Dis 2000, 182:1402-1408.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2334/6/53/prepub